RESUMEN
To determine the prevalence and incidence of hepatitis C virus (HCV) infections among haemodialysis patients, a large prospective multicentre trial was conducted in the German Federal State of North Rhine-Westphalia. Sera obtained from the recruited patients in two separate sampling rounds run 1 year apart were analysed for both anti-HCV antibodies and HCV RNA. HCV RNA positive samples were also genotyped by direct sequencing of an HCV core fragment. In the first and second rounds, 150 (5.2%) of 2909 and 114 (5.4%) of 2100 patients were anti-HCV positive, respectively, and 4% of individuals were viraemic. Evaluation of potential risk factors in a case-control study indicated that the factors 'foreign country of birth', 'blood transfusions given before 1991' and 'duration of treatment on haemodialysis' were associated with the risk of HCV infection. Among the 2100 patients of whom 'paired' serum samples from both rounds were available for testing, not a single 'de novo' HCV infection could be recorded. The fact that in a subset of about 20% of these patients no nosocomial GB virus C (GBV-C) transmission occurred during the observational period suggests that the lack of HCV seroconversions was not only attributable to the isolation of HCV-infected patients but also to the strict adherence to so-called universal hygienic precautions for infection control maintained in the participating dialysis centres.
Asunto(s)
Diálisis/efectos adversos , Infecciones por Flaviviridae/epidemiología , Virus GB-C/aislamiento & purificación , Hepacivirus/aislamiento & purificación , Hepatitis C/epidemiología , Hepatitis Viral Humana/epidemiología , Adulto , Animales , Estudios de Cohortes , Femenino , Infecciones por Flaviviridae/virología , Genotipo , Alemania/epidemiología , Investigación sobre Servicios de Salud , Hepatitis C/virología , Anticuerpos contra la Hepatitis C/sangre , Hepatitis Viral Humana/virología , Humanos , Incidencia , Control de Infecciones , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , ARN Viral/sangre , ARN Viral/genética , Factores de Riesgo , Suero/inmunología , Suero/virologíaRESUMEN
We investigated prospectively the efficacy of ezetimibe in addition to statin therapy in stable renal transplant patients in whom hypercholesterolemia was not sufficiently treated. Eighteen renal transplant patients received 10 mg ezetimibe once daily in addition to high-dose statin therapy for uncontrolled hypercholesterolemia. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, Tacrolimus (Tac)- and Cyclosporine A (CsA) blood levels, creatinine, urea, liver enzymes, electrolytes and creatinkinase (CK) were measured before initiation of ezetimibe therapy, after 7 days, 6 weeks and 3 months. Cholesterol concentrations decreased significantly (p < 0.005) from 264 +/- 46 mg/dL at baseline to 205 +/- 48 mg/dL after 1 week to 202 +/- 48 mg/dL after 6 weeks and 212 +/- 40 mg/dL after 3 months (reduction after 3 months 21 +/- 10%). LDL-concentrations decreased significantly (p < 0.005) from 178 +/- 41 mg/dL at baseline to 129 +/- 35 mg/dL after 1 week to 123 +/- 25 after 6 weeks and to 117 +/- 40 mg/dL after 3 months (reduction after 3 months 37 +/- 14%). Two patients stopped ezetimibe therapy due to nausea and muscle pain without CK elevation. Significant changes of CsA and Tac blood levels, liver and muscle enzymes were not observed. Ezetimibe seems to be an effective therapy for uncontrolled hypercholesterolemia in renal transplant patients when combined with high-dose statin therapy.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Azetidinas/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Trasplante de Riñón , Adulto , Anciano , Azetidinas/efectos adversos , Colesterol/sangre , Ciclosporina/sangre , Quimioterapia Combinada , Ezetimiba , Ácidos Grasos Monoinsaturados/uso terapéutico , Femenino , Fluvastatina , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Indoles/uso terapéutico , Hígado/enzimología , Masculino , Persona de Mediana Edad , Músculo Esquelético/enzimología , Pravastatina/uso terapéutico , Simvastatina/uso terapéutico , Tacrolimus/sangreRESUMEN
Hypertension is the most important risk factor for stroke and vascular dementia. Antihypertensive treatment reduces stroke risk by 40%. Most probably all antihypertensive drugs are equally effective with the exception of alpha-blockers. Blood pressure is increased in many patients with acute stroke. In this phase sudden drops in blood pressure should be avoided. The combination of an ACE-inhibitor and a diuretic reduced strokes by 28% after TIA or a first stroke. Whether this is a drug specific effect or due to lowering blood pressure per se is investigated at the moment.